S-adenosyl-methionine in depression

A comprehensive review of the literature

George I. Papakostas, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalReview article

68 Citations (Scopus)

Abstract

As many as 29% to 46% of patients with major depressive disorder (MDD) show only partial or no response to an adequate course of an antidepressant. The current practice is to increase the dose, switch to another antidepressant, or to combine the initial antidepressant with an antidepressant of a different class or a non-antidepressant agent. A growing number of studies have also been directed toward exploring the potential use of augmenting traditional antidepressants with nonpharmaceutic supplements, or even using such supplements as monotherapy for depression. S-adenosyl-methionine (SAMe) is one such compound. Compared with many other nonpharmaceutic supplements, SAMe has been extensively studied, and impressive literature extending back three decades suggests the antidepressant efficacy of SAMe. In the present work, the authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use of SAMe for the treatment of MDD. Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system.

Original languageEnglish (US)
Pages (from-to)460-466
Number of pages7
JournalCurrent Psychiatry Reports
Volume5
Issue number6
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Methionine
Antidepressive Agents
Depression
Major Depressive Disorder
Central Nervous System

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

S-adenosyl-methionine in depression : A comprehensive review of the literature. / Papakostas, George I.; Alpert, Jonathan E.; Fava, Maurizio.

In: Current Psychiatry Reports, Vol. 5, No. 6, 12.2003, p. 460-466.

Research output: Contribution to journalReview article

Papakostas, George I. ; Alpert, Jonathan E. ; Fava, Maurizio. / S-adenosyl-methionine in depression : A comprehensive review of the literature. In: Current Psychiatry Reports. 2003 ; Vol. 5, No. 6. pp. 460-466.
@article{e769922df18e499b8d2771b89d26c282,
title = "S-adenosyl-methionine in depression: A comprehensive review of the literature",
abstract = "As many as 29{\%} to 46{\%} of patients with major depressive disorder (MDD) show only partial or no response to an adequate course of an antidepressant. The current practice is to increase the dose, switch to another antidepressant, or to combine the initial antidepressant with an antidepressant of a different class or a non-antidepressant agent. A growing number of studies have also been directed toward exploring the potential use of augmenting traditional antidepressants with nonpharmaceutic supplements, or even using such supplements as monotherapy for depression. S-adenosyl-methionine (SAMe) is one such compound. Compared with many other nonpharmaceutic supplements, SAMe has been extensively studied, and impressive literature extending back three decades suggests the antidepressant efficacy of SAMe. In the present work, the authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use of SAMe for the treatment of MDD. Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system.",
author = "Papakostas, {George I.} and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2003",
month = "12",
language = "English (US)",
volume = "5",
pages = "460--466",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - S-adenosyl-methionine in depression

T2 - A comprehensive review of the literature

AU - Papakostas, George I.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2003/12

Y1 - 2003/12

N2 - As many as 29% to 46% of patients with major depressive disorder (MDD) show only partial or no response to an adequate course of an antidepressant. The current practice is to increase the dose, switch to another antidepressant, or to combine the initial antidepressant with an antidepressant of a different class or a non-antidepressant agent. A growing number of studies have also been directed toward exploring the potential use of augmenting traditional antidepressants with nonpharmaceutic supplements, or even using such supplements as monotherapy for depression. S-adenosyl-methionine (SAMe) is one such compound. Compared with many other nonpharmaceutic supplements, SAMe has been extensively studied, and impressive literature extending back three decades suggests the antidepressant efficacy of SAMe. In the present work, the authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use of SAMe for the treatment of MDD. Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system.

AB - As many as 29% to 46% of patients with major depressive disorder (MDD) show only partial or no response to an adequate course of an antidepressant. The current practice is to increase the dose, switch to another antidepressant, or to combine the initial antidepressant with an antidepressant of a different class or a non-antidepressant agent. A growing number of studies have also been directed toward exploring the potential use of augmenting traditional antidepressants with nonpharmaceutic supplements, or even using such supplements as monotherapy for depression. S-adenosyl-methionine (SAMe) is one such compound. Compared with many other nonpharmaceutic supplements, SAMe has been extensively studied, and impressive literature extending back three decades suggests the antidepressant efficacy of SAMe. In the present work, the authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use of SAMe for the treatment of MDD. Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=2942673042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942673042&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 460

EP - 466

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 6

ER -